Form 10-Q Summary
Filing identity: The supplied filing is for Galecto, Inc. (Nasdaq: GLTO), not Damora Therapeutics, Inc. It covers the quarter and six months ended June 30, 2023 and was filed July 31, 2023. The financial statements are unaudited and prepared under U.S. GAAP.
Business Context and Reporting Period
Galecto is a clinical-stage biotechnology company developing small-molecule inhibitors targeting galectin-3 and LOXL2 for fibrotic diseases and cancer. Its principal Phase 2 programs are GB0139 for idiopathic pulmonary fibrosis, GB1211 for liver cirrhosis and oncology, and GB2064 for myelofibrosis. The company has no approved products and no product revenue.
Financial Performance and Position
| Metric | Three months ended June 30, 2023 | Six months ended June 30, 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $8.1 million | $18.5 million |
| General and administrative expense | $3.1 million | $6.2 million |
| Total operating expenses | $11.2 million | $24.7 million |
| Operating loss | $11.2 million | $24.7 million |
| Other income, net | $0.4 million | $0.9 million |
| Net loss | $10.7 million | $23.7 million |
| Net loss per share | $0.41 | $0.91 |
- No meaningful revenue or profitability margins are reported because the company has no product sales.
- Cash used in operating activities was $17.0 million for the six months ended June 30, 2023, compared with $21.6 million in the prior-year period.
- Cash, cash equivalents and marketable securities totaled $52.1 million at June 30, 2023, consisting of $23.0 million of cash and cash equivalents and $29.2 million of current marketable securities.
- Total assets were $58.8 million, current liabilities were $14.9 million, and stockholders’ equity was $43.7 million.
- The filing shows no debt financing or material borrowing; lease liabilities totaled $626,000, including $420,000 classified as current.
- The company raised $2.7 million net from issuance of common stock under its at-the-market program during the first six months.
Material Changes Versus the Prior Comparable Period
- Quarterly research and development expense decreased 41.0% to $8.1 million, primarily because of lower clinical-trial activity and chemistry, manufacturing and controls costs.
- Six-month research and development expense decreased 31.5% to $18.5 million, mainly due to the timing of clinical-trial activities.
- Quarterly general and administrative expense decreased 10.1%; six-month expense decreased 12.9%, primarily due to lower insurance and other administrative costs.
- Quarterly net loss improved 36.4% from $16.9 million to $10.7 million; six-month net loss improved 29.8% from $33.8 million to $23.7 million.
- Interest income increased as cash and marketable securities generated higher returns.
- Cash, cash equivalents and marketable securities declined from $66.1 million at December 31, 2022 to $52.1 million at June 30, 2023.
- Common shares outstanding increased to 27.0 million at June 30, 2023 from 25.7 million at December 31, 2022, primarily reflecting ATM issuance.
Guidance, Outlook, Risks and Unusual Items
- Management expects existing cash, cash equivalents and marketable securities to fund operating and capital requirements into the second half of 2024, subject to assumptions that may prove inaccurate.
- Additional financing will be required to continue clinical development and fund operations. Potential sources include equity or debt offerings, collaborations, licensing transactions and reductions or discontinuation of programs.
- Management expects continued losses and negative operating cash flow for the foreseeable future and does not expect product revenue unless a candidate receives regulatory approval and is commercialized.
- Topline results for the GB0139 GALACTIC-1 Phase 2b IPF trial were expected in August 2023.
- The company stopped enrolling additional patients in the GB2064 MYLOX-1 trial after the predefined antifibrotic activity target was exceeded and expected topline results in the second half of 2023.
- The company planned to initiate a Phase 2a GB1211 trial in decompensated NASH cirrhosis in early 2024, subject to additional financing or a collaboration.
- Clinical development remains subject to enrollment, safety, efficacy, regulatory, manufacturing, intellectual-property and financing risks. The company reported no material changes to previously disclosed risk factors and no material legal proceedings.
- Stock-based compensation was $2.9 million for the first six months, and unrecognized stock-based compensation expense was $9.9 million at June 30, 2023.
Investor Verification Checklist
- Confirm that the intended issuer is Galecto, Inc., rather than Damora Therapeutics, Inc.
- Verify the timing and results of the expected GALACTIC-1 and MYLOX-1 topline disclosures after the filing date.
- Assess whether the reported cash runway into the second half of 2024 remains valid given clinical spending and financing conditions.
- Review subsequent equity offerings, ATM usage, dilution and any debt or collaboration financing.
- Evaluate clinical safety and efficacy data for GB0139, GB1211 and GB2064, including the adverse events observed in the GALLANT-1 trial.
- Review the company’s ability to obtain regulatory approval, maintain financing, and protect its intellectual property.